The recent outbreak of coronavirus disease 2019 (COVID-19), triggered by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses an enormous threat to global public health and economies. Human coronaviruses normally cause no or mild respiratory disease but in the past two decades, potentially fatal coronavirus infections have emerged, causing respiratory tract illnesses such as pneumonia and bronchitis. These include severe acute respiratory syndrome coronavirus (SARS-CoV), followed by the Middle East respiratory syndrome coronavirus (MERS-CoV), and recently the SARS-CoV-2 coronavirus outbreak which emerged in Wuhan, China, in December 2019. Currently, most COVID-19 patients receive traditional supportive care including breathing assistance. To halt the ongoing spread of the pandemic SARS-CoV-2 coronavirus and rescue individual patients, established drugs and new therapies are under evaluation. Since it will be some time until a safe and effective vaccine will be available, the immediate priority is to harness innate immunity to accelerate early antiviral immune responses. Secondly since excessive inflammation is a major cause of pathology, targeted anti-inflammatory responses are being evaluated to reduce inflammation-induced damage to the respiratory tract and cytokine storms. Here, we highlight prominent immunotherapies at various stages of development which aim for augmented anti-coronavirus immunity and reduction of pathological inflammation. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; SARS-CoV-2; cytokine; innate immunity; lung.
This article is protected by copyright. All rights reserved.
Features, Evaluation and Treatment Coronavirus (COVID-19).2020 Apr 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. StatPearls. 2020 Jan–. PMID: 32150360 Free Books & Documents. Review.
Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19).Clin Exp Pediatr. 2020 Apr;63(4):119-124. doi: 10.3345/cep.2020.00493. Epub 2020 Apr 2. Clin Exp Pediatr. 2020. PMID: 32252141 Free PMC article.
Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.J Virol. 2016 Sep 12;90(19):8924-33. doi: 10.1128/JVI.01429-16. Print 2016 Oct 1. J Virol. 2016. PMID: 27466418 Free PMC article.
The novel zoonotic COVID-19 pandemic: An expected global health concern.J Infect Dev Ctries. 2020 Mar 31;14(3):254-264. doi: 10.3855/jidc.12671. J Infect Dev Ctries. 2020. PMID: 32235085
[Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):571-592. doi: 10.13345/j.cjb.200115. Sheng Wu Gong Cheng Xue Bao. 2020. PMID: 32347053 Review. Chinese.